Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-16 | Elicera Therapeutics | Elicera Therapeutics publicerar årsredovisningen för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Elicera Therapeutics | Elicera Therapeutics publishes the annual report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Elicera Therapeutics | Kallelse till årsstämma i Elicera Therapeutics AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Elicera Therapeutics | Elicera Therapeutics: Nomination committee proposes CMC specialist to Elicera's board of directors | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Elicera Therapeutics: Nomination committee proposes CMC specialist to Elicera’s board of directorsElicera informed in a press release on October 31, 2023 that a Nomination Committee was formed ahead of the annual meeting on May 16, 2024. The Nomination Committee consists of Magnus Essand (chair), Di Yu and Jamal El-Mosleh, that together controlled 47.1 of the votes. The Nomination Committee has thus unanimously proposed a re-election of the current Board: Agneta Edberg (chair), Magnus Essand, Christina Herder and Margareth Jorvid as ordinary members and Di Yu as deputy member. Jan Zetterberg has declined re-election. Sharon Longhurst holds a PhD in Virology from the University of Warwick and BSc in Biochemistry from the University of Surrey. Sharon Longhurst (born 1969) has more than 20 years’ experience in CMC development of biological medicinal products, specializing in Advanced Therapy Medicinal Products (ATMP). Her previous positions include VP of Development at Gadeta BV, Head of CMC at Immunicum AB (now Mendus) and Akari Therapeutics. She has also worked as a Senior Pharmaceutical Asessor at the MHRA (UK competent authority). Current assignments include Director at Advanced Biologics Consulting Ltd where she provides CMC consulting services to biotech companies. Sharon Longhurst is independent in relation to the senior executives of the company and major shareholders. She is, however, contracted to provide independent CMC consulting services to Elicera. The Committee also proposes the re-election of RSM, with signatory auditor Kristoffer Håkansson. The Nomination Committee proposes remuneration to the board. Payment of SEK 240,000 is proposed for the Chairman of the Board and SEK 120,000 is proposed for external members (eg Christina Herder, Margareth Jorvid and Sharon Longhurst). The auditor will be remunerated according to the approved offer. The Annual General Meeting will be held on May 16, 2024, at 1:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm) and attorney Mats Dahlberg has been proposed to chair the Meeting. For more information, please contact: Jamal El-Mosleh, CEO at Elicera Therapeutics AB Mail: Phone: +46 (0) 703 31 90 51 Webb: www.elicera.com ( https://www.elicera.com/sv/home ) Certified Adviser The Company’s Certified Adviser is Carnegie Investment Bank AB (publ). The information was submitted for publication distributed through the contact person below at 12;16 CET on March 28, 2024. About Elicera Therapeutics AB Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. The company’s certified advisor is Carnegie Investment Bank AB (publ), www.carnegie.se. For additional information, visit www.elicera.com. |
||||
2024-03-28 | Elicera Therapeutics | Elicera Therapeutics valberedning föreslår CMC specialist till styrelsen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-25 | Elicera Therapeutics | Elicera Therapeutics meddelar sista dag för handel i BTU och första dag för handel i teckningsoptioner serie TO2 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-25 | Elicera Therapeutics | Elicera Therapeutics announces the last day of trading in BTU and the first day of trading in warrants of series TO2 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-22 | Elicera Therapeutics | Elicera Therapeutics AB byter Certified Adviser och Likviditetsgarant till Mangold Fondkommission AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-22 | Elicera Therapeutics | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-11 | Elicera Therapeutics | Elicera Therapeutics announces outcome in rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-11 | Elicera Therapeutics | Elicera Therapeutics offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-07 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera collaborates with US cancer centre to evaluate iTANK | Pressreleaser | Visa Stäng |
|
||||
2024-03-07 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera i samarbete med cancercenter i USA för utvärdering av iTANK | Pressreleaser | Visa Stäng |
|
||||
2024-03-06 | Elicera Therapeutics | Elicera Therapeutics: Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-06 | Elicera Therapeutics | Elicera Therapeutics: Elicera ingår avtal med framstående amerikanskt cancercenter för att utvärdera användningen av iTANK i T-cellsreceptorterapier | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Elicera Therapeutics presenteras på Life Sciencedagen i Göteborg den 6 mars | Pressreleaser | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Elicera Therapeutics erhåller utökade teckningsåtaganden från styrelse och ledning i den pågående företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Last day of trading in unit rights in Elicera Therapeutics rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Elicera Therapeutics | Sista dag för handel med uniträtter i Elicera Therapeutics företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-29 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Emission ska ta Eliceras ELC-301 igenom klinisk studie | Pressreleaser | Visa Stäng |
|
||||
2024-02-27 | Elicera Therapeutics | Elicera Therapeutics: Eliceras vd till BioStock: "Den viktigaste händelsen sedan Eliceras start | Pressreleaser | Visa Stäng |
|
||||
2024-02-26 | Penser Future by Carnegie | Penser Future by Carnegie: Intervju med Elicera Therapeutics- Carnegie Investment Bank - 26 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-23 | Elicera Therapeutics | The subscription period in Elicera Therapeutics' rights issue of units starts today | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-23 | Elicera Therapeutics | Teckningsperioden i Elicera Therapeutics företrädesemission av units inleds idag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Elicera Therapeutics | Elicera Therapeutics publishes prospectus in connection with rights issue of units | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Elicera Therapeutics | Elicera Therapeutics offentliggör prospekt i samband med företrädesemission av units | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-20 | Elicera Therapeutics | Kommuniké från extra bolagsstämma i Elicera Therapeutics AB (publ) den 20 februari 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-19 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Full speed ahead for Elicera in 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-19 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Full fart framåt för Elicera under 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics abstract om iTANK-plattformens potential att förstärka CAR T-cellbehandling av solida tumörer accepterad för presentation på ISCT 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics: Elicera invites to investor meetings on February 28[th] and 29[th] 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Elicera Therapeutics | Elicera Therapeutics: Elicera bjuder in till investerarträffar 28 och 29 februari 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-14 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera får grönt ljus för klinisk CAR T-studie | Pressreleaser | Visa Stäng |
|
||||
2024-02-14 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera gets green light for CAR T clinical study | Pressreleaser | Visa Stäng |
|
||||
2024-02-14 | Penser Future by Carnegie | Penser Future by Carnegie: Elicera Therapeutics - Grönt ljus från Läkemedelsverket | Pressreleaser | Visa Stäng |
|
||||
2024-02-13 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Bokslutskommuniké 1 januari - 31 december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-13 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Year-End Report 1 January - 31 December 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-09 | Elicera Therapeutics | Elicera Therapeutics erhåller godkännande att initiera den kliniska fas I/II-studien CARMA med CAR T-cellsterapin ELC-301 i B-cellslymfom | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-09 | Elicera Therapeutics | Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | Elicera Therapeutics: NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | KALLELSE TILL extra bolagsSTÄMMA I Elicera Therapeutics AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | Elicera Therapeutics: Elicera's Board of Directors proposes a rights issue of units of approximately SEK 64 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Elicera Therapeutics | Elicera Therapeutics: Eliceras styrelse föreslår en företrädesemission av units om cirka 64 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-17 | Elicera Therapeutics | Elicera Therapeutics medgrundare Magnus Essand inbjuden att presentera bolagets CAR T-cellsprojekt vid världens största konferens om cancerimmunterapi, CICON | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-17 | Elicera Therapeutics | Elicera Therapeutics' co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-09 | Elicera Therapeutics | Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-09 | Elicera Therapeutics | Elicera Therapeutics deltar i ett samarbetsprojekt för utveckling av förbättrad CAR T-cellstillverkning som tilldelats forskningsstöd om 850 TSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics medgrundare får anslag på totalt 4,8 MSEK från Barncancerfonden för att stödja CAR T-forskning | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Elicera Therapeutics | Elicera Therapeutics lämnar in GMP-valideringsdata till Läkemedelsverket för CARMA-studien i syfte att komplettera den villkorat godkända kliniska prövningsansökan | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Elicera Therapeutics | Elicera Therapeutics: BioStock: FDA CAR T investigation does not affect Elicera | Pressreleaser | Visa Stäng |
|
||||
2023-12-21 | Elicera Therapeutics | Elicera Therapeutics: BioStock: FDA:s CAR T-utredning påverkar inte Elicera | Pressreleaser | Visa Stäng |
|
||||
2023-11-30 | Elicera Therapeutics | Elicera Therapeutics AB byter Certified Adviser och Likviditetsgarant till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Elicera Therapeutics | Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | Elicera Therapeutics | Elicera Therapeutics: BioStock: CAR T deal puts spotlight on Elicera's technology | Pressreleaser | Visa Stäng |
|
||||
2023-11-29 | Elicera Therapeutics | Elicera Therapeutics: BioStock: CAR T-affär sätter fokus på Eliceras teknik | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera's CEO: " iTANK has great potential in treating solid tumours" | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Eliceras vd: "iTANK har hög potential vid behandling av solida tumörer" | Pressreleaser | Visa Stäng |
|
||||
2023-11-15 | Penser Future | Penser Future: Närmar sig en rad viktiga värdehöjande milstolpar - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-11-14 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Delårsrapport 1 januari - 30 september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Elicera Therapeutics | Elicera Therapeutics: Nomination Committee for Elicera therapeutics appointed | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Elicera Therapeutics | Elicera Therapeutics utser valberedning | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Elicera Therapeutics | Elicera Therapeutics presenterar på BioStock Life Science Summit den 26 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-09-08 | Elicera Therapeutics | Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-08 | Elicera Therapeutics | Elicera Therapeutics får besked om beviljande av kinesiskt patent som skyddar iTANK-plattformen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-30 | Penser Future | Penser Future: I väntan på studiestart - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-08-29 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Delårsrapport 1 januari - 30 juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-29 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-15 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera's potential in cancer therapy published in Nature Communications | Pressreleaser | Visa Stäng |
|
||||
2023-08-15 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Eliceras potential inom cancerterapi publicerad i Nature Communications | Pressreleaser | Visa Stäng |
|
||||
2023-08-10 | Elicera Therapeutics | Elicera Therapeutics publicerar en vetenskaplig artikel i Nature Communications om CAR T-konstruktionen i ELC-401 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-10 | Elicera Therapeutics | Elicera Therapeutics publishes a scientific article in Nature Communications about the CAR T construct in the ELC-401 program | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-13 | Elicera Therapeutics | BioStock: Elicera Therapeutics receives important EU patent | Pressreleaser | Visa Stäng |
|
||||
2023-07-13 | Elicera Therapeutics | BioStock: Elicera Therapeutics säkrar viktigt EU-patent | Pressreleaser | Visa Stäng |
|
||||
2023-07-11 | Elicera Therapeutics | Elicera Therapeutics får besked om beviljande av europeiskt patent som skyddar iTANK[TM]-plattformen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-11 | Elicera Therapeutics | Elicera Therapeutics receives Notice of Allowance for European patent protecting the iTANK[TM] platform | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-30 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera uppdaterar i samband med Cancer Immunotherapy Month | Pressreleaser | Visa Stäng |
|
||||
2023-06-30 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Elicera gives an update in Cancer Immunotherapy Month | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Elicera Therapeutics | BioStock Life Science Spring Summit with Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-31 | Elicera Therapeutics | BioStock Life Science Spring Summit med Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Well-financed Elicera prepared for clinic and business development | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Välfinansierat Elicera beredda för klinik och affärsutveckling | Pressreleaser | Visa Stäng |
|
||||
2023-05-17 | Penser Future | Penser Future: Väl rustad för pågående och planerade kliniska studier - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-16 | Elicera Therapeutics | Kommuniké från årsstämma i Elicera Therapeutics AB (publ) den 16 maj 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Elicera Therapeutics | Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-15 | Penser Future | Penser Future: Intervju med Elicera Therapeutics - Erik Penser Bank - 15 maj 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-05-10 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Janssens CAR T-avtal ger stöd till Eliceras vision | Pressreleaser | Visa Stäng |
|
||||
2023-05-10 | Elicera Therapeutics | Elicera Therapeutics: BioStock: Janssen CAR T deal supports Elicera's vision | Pressreleaser | Visa Stäng |
|
||||
2023-05-09 | Elicera Therapeutics | BioStock Studio: Elicera Therapeutics om Läkemedelsverkets villkorade godkännande | Pressreleaser | Visa Stäng |
|
||||
2023-05-03 | Penser Future | Penser Future: Miljardaffär inom NHL-området - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-02 | Penser Future | Penser Future: Villkorat godkännande från Läkemedelsverket - Elicera Therapeutics | Pressreleaser | Visa Stäng |
|
||||
2023-05-02 | Carlsquare | Carlsquare: Mrkt BUZZ Elicera Therapeutics: Ett steg närmare klinik för CAR T-projekt | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Elicera Therapeutics | Elicera Therapeutics receives conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-28 | Elicera Therapeutics | Elicera Therapeutics erhåller villkorat godkännande från Läkemedelsverket för ansökan om klinisk prövning (CARMA-studien) med CAR T-cellsterapin ELC-301 | Pressreleaser | Ladda ner | Visa Stäng |
|